This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Nonalcoholic steatohepatitis (NASH) is a type of liver disease that is characterized by fat accumulation in the liver, inflammation, and potential liver damage. It is a severe form of nonalcoholic fatty liver disease (NAFLD) and can lead to cirrhosis and liver cancer. The exact cause of NASH is unknown, however, it is believed to be associated with risk factors such as obesity, diabetes, and high cholesterol. NASH is caused by an accumulation of fat in the liver due to an unhealthy diet or lifestyle. When the fat accumulates, it causes an increase in inflammation, which can lead to tissue damage. This tissue damage can be seen on liver biopsy, which is used to diagnose NASH. Symptoms of NASH can include fatigue, abdominal pain, and jaundice. Treatment of NASH focuses on reducing the risk factors associated with the disease. This includes lifestyle modifications such as weight loss, increased physical activity, and a healthy diet. Medications such as insulin sensitizers, cholesterol-lowering agents, and antioxidants may also be prescribed. In severe cases of NASH, liver transplantation may be necessary. It is important to note that NASH is a serious condition and can lead to complications if left untreated. It is important to consult a physician to discuss the best treatment options for your particular case. With the right lifestyle changes, medications, and support, NASH can be managed and complications can be avoided.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States